KIYAN MEDICAL Corporation (CEO: Hiroyoshi Hata and Akira Suzuki, hereinafter referred to as “KIYAN MEDICAL”) and Biozipcode Inc. (CEO: Fumihisa Kojima, hereinafter referred to as “Biozipcode”) announced today their business partnership in the development of a cure for diabetes and research and development of cancer treatment drugs. This partnership is expected to accelerate the development and technical cooperation of new drugs, including those for diabetes and cancer treatment, especially those containing boron-based drugs.

Biozipcode, a venture originating from Shiga University of Medical Science, specializes in the research of diabetes treatment drugs. It is advancing the development of diagnostic and therapeutic drugs targeting abnormal hematopoietic stem cells that make the cure of diabetes difficult, and also engages in contracted research including regenerative medicine, academic guidance on technology, and pharmacological testing.

On the other hand, KIYAN MEDICAL, established on the foundation of a pharmaceutical company, is committed to realizing medical care from basic research to hospitals. Through this partnership, the comprehensive research and development capabilities of KIYAN MEDICAL and the innovative cell-targeting technology of Biozipcode will be combined, enabling the development of more effective therapeutic drugs.

Both companies aim to revolutionize the treatment of diseases such as diabetes and cancer through this partnership. This significant effort, including the development of a cure for diabetes, is hoped to bring new hope to patients worldwide.